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Despite a growing level of comfort in managing patients on long-term left
ventricular assist device (LVAD) support, certain areas remain poorly studied.
One of them is managing anticoagulation when the international normalized
ratio (INR) becomes subtherapeutic. A few studies addressed this issue in
patients undergoing invasive procedures or surgeries when the routine
maintenance anticoagulation with warfarin needs to be interrupted.1 But when
the INR becomes subtherapeutic as a result of multiple factors such as
missed doses, administration of antibiotics for a concomitant infection, or
change in the diet, each individual program has to establish their own protocol
as no guidelines provide clear-cut directions.
This problem is not unique for the LVAD field. Patients who are on chronic
anticoagulation for other conditions encounter similar challenges. In cases of
surgery or procedure, no bridging is currently recommended for those who
take warfarin for atrial fibrillation, because the bridging increases the rate of
bleeding events without reducing thromboembolism.2, 3 However, some
patients with mechanical prosthetic valves and additional risk factors for
thromboembolic events require bridging. One of the factors creating a higher
risk for thromboembolic events in patients with mechanical prosthetic aortic
valves is a low left ventricular ejection fraction, which is seen in patients on
LVAD support. And yet, even detailed valvular guidelines do not give any
specific directions for bridging in cases where the INR drifts to subtherapeutic
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level without intentional interruption of anticoagulation.4, 5 Therefore, studies
filling this gap in knowledge are of certain interest.
In volume 6, issue 2 of The VAD Journal, we published a paper by Rainess et
al.6 who reported their experience with managing subtherapeutic INRs, mostly
in patients with HeartMate II (HM II) (Thoratec, Pleasanton, CA). Although, the
cohort did include some HeartMate 3-supported patients. In their program
(Wake Forest University), pharmacists manage anticoagulation according to
the institutional protocol, which allows bridging with low molecular weight
heparin when INR decreases to less than 1.8. The study is unique because the
patients did NOT require interruption of anticoagulation for any purpose. In all
instances, the INR decreased because of dietary variations, recent dose
changes, skipped doses, medication interactions, etc. Almost half of their
patients had a history of hemolysis or pump thrombosis. After analyzing 155
bridging episodes, the authors reported systemic bleeding events in 9% of the
patients and localized bleeding in 10%. Importantly, no event resulted in
hospitalization or blood transfusion; this rate seems to be excessive
considering a relatively minor deviation of INR from the therapeutic range, and
it raises a question about an appropriate threshold for bridging initiation.
Several studies regarding reduced anticoagulation in LVAD patients provide
some insights. Reversal of anticoagulation for procedures in patients on
LVAD appear to be safe in terms of thromboembolic risks.7, 8 After
anticoagulation reversal with vitamin K or Factor VII, there was only one
thromboembolism in 25 patients who experienced a total of 38
anticoagulation reversal events.7 Another prospective study analyzed data on
14 patients whose anticoagulation, or both anticoagulation and antiplatelet
therapy, was discontinued for more than 30 days due to gastrointestinal
bleeding.9 The mean duration off warfarin was 392 days (range, 31 - 1,980
days), with the total cumulative time off warfarin being 15 patient-years. Five
(35.7%) patients remained off warfarin for at least 1 year. One patient had a
pump thrombus due to device malpositioning that required a device exchange
after being off warfarin for 1.3 years.9
Some authors also reported smaller groups of patients with anticoagulation
interruption for bleeding and without bridging. Thus, per John et al.,10 seven
patients safely discontinued warfarin for a total duration of 39.1 patientmonths.
In the study by Bhatia et al.,1 which is referenced by Reiness, et al.,6 there
was a fourfold increase in major bleeding events during the bridged period in
the enoxaparin group, although they initiated bridging at a lower INR (1.46)
than Rainess et al. (1.62).
Several years ago, we reviewed our data on utilizing bridging with low
molecular weight heparin in patients with HMII devices undergoing surgeries
or invasive procedures.8 We found that in patients who were bridged, the rate
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of bleeding episodes was significantly higher than in those who continued
warfarin throughout the surgery or who temporarily discontinued warfarin with
no bridging (Figure 1).
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Figure 1. Rate of thromboembolic events in patients on HeartMate II support
depending on the strategy of anticoagulation management during elective
surgery/procedure.8

In summary, studies such as Rainess et al.6 fill an important knowledge gap.
From our standpoint, a 20% risk in bleeding, which includes a 9% risk of
systemic bleeding, is a too high price to pay for such a minor decrease in
INR. Perhaps tolerating a subtherapeutic INR for a few days would be a safer
approach. A specific cutoff of the INR value triggering bridging should be a
subject of a randomized study, but setting the bar at 1.8 may represent an
excessively aggressive strategy.

References:
1.
Bhatia A, Juricek C, Sarswat N, Adatya S, Kim G, Sayer G, et al.
Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated
with Enoxaparin as Bridge to Therapeutic International Normalized Ratio.
ASAIO J. 2018;64(2):140-6.
2.
Ayoub K, Nairooz R, Almomani A, Marji M, Paydak H, Maskoun W.
Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring
Temporary Interruption of Anticoagulation: Evidence from Meta-analysis. J
Stroke Cerebrovasc Dis. 2016;25(9):2215-21.

To Bridge or Not to Bridge?

Page 3 of 4

The VAD Journal: The journal of mechanical assisted circulation and heart failure

3.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn
AS, et al. Perioperative Bridging Anticoagulation in Patients with Atrial
Fibrillation. N Engl J Med. 2015;373(9):823-33.
4.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd,
Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC
Guideline for the Management of Patients With Valvular Heart Disease: A
Report of the American College of Cardiology/American Heart Association
Task Force on Clinical Practice Guidelines. J Am Coll Cardiol.
2017;70(2):252-89.
5.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd,
Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients
with valvular heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. J
Am Coll Cardiol. 2014;63(22):e57-185.
6.
Rainess RA, Alderman L, Cicci T, Yoder M, Pisani B, O’Neill T, et al.
Evaluation of Outpatient Anticoagulation Bridging After Left Ventricular Assist
Device Implantation. 2020;6(2):e2020626.
7.
Jennings DL, Jacob M, Chopra A, Nemerovski CW, Morgan JA,
Lanfear DE. Safety of Anticoagulation Reversal in Patients Supported with
Continuous-flow Left-ventricular Assist Devices. ASAIO J. 2014;60(4):381-4.
8.
Guglin M, Hart A, Ross MJ. Anticoagulation Strategy in Patients with
HeartMate II Undergoing Elective Surgery. J Card Fail. 2019;25(S8):S53.
9.
Kamdar F, Eckman P, John R. Safety of discontinuation of anticoagulation in patients with continuous-flow left ventricular assist devices. J
Heart Lung Trasplant. 2014;33(3):316-8.
10.
John R, Kamdar F, Liao K, Colvin-Adams M, Miller L, Joyce L, et al.
Low thromboembolic risk for patients with the Heartmate II left ventricular
assist device. J Thorac Cardiovasc Surg. 2008;136(5):1318-23.

To Bridge or Not to Bridge?

Page 4 of 4

